Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion.

Abstract

INTRODUCTION:

Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) chemotherapy and is licensed for the treatment of breast and gastrointestinal cancers. Multifocal inflammatory leukoencephalopathy has been associated with intravenous 5-FU, but only a few cases of capecitabine-induced encephalopathy have been reported.

SETTING:

We describe here a case of encephalopathy following administration of Epirubicin/ Cisplatin/Capecitabine chemotherapy, review those cases previously described and suggest recommendations for management.

RESULTS:

Symptoms of neurotoxicity from 5-FU and capecitabine usually include confusion, ataxia, nystagmus, dysarthria, sensory loss, and memory loss. Withdrawal of the drug generally leads to improvement of symptoms and steroids are of only questionable benefit.

CONCLUSION:

Patients on fluouropyrimidine drugs with new neurological symptoms should be investigated with brain MRI scan and the drug should be withdrawn until symptoms resolve. Dihydropyrimidine dehydrogenase deficiency should be excluded and ideally an alternative chemotherapy regime sought. We would encourage reporting of such incidences to gain a clearer picture of the incidence and optimal management.

• Authors: Karen Tipples, Rajeev B Kolluri, Sherif Raouf
• Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (J Oncol Pharm Pract) Vol. 15 Issue 4 Pg. 237-9 (Dec 2009) ISSN: 1477-092X [Electronic] England
• PMID: 19276137 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibiotics, Antineoplastic
• Antimetabolites, Antineoplastic
• Antineoplastic Agents
• Deoxycytidine
• Epirubicin
• Capecitabine
• Cisplatin
• Fluorouracil

Topics

• Adenocarcinoma (complications, drug therapy, pathology)
• Antibiotics, Antineoplastic (administration & dosage)
• Antimetabolites, Antineoplastic (administration & dosage, adverse effects, therapeutic use)
• Antineoplastic Agents (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Brain Diseases (cerebrospinal fluid, chemically induced, psychology)
• Capecitabine
• Cisplatin (administration & dosage)
• Deoxycytidine (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
• Epirubicin (administration & dosage)
• Esophageal Neoplasms (complications, drug therapy, pathology)
• Fluorouracil (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
• Humans
• Liver Neoplasms (drug therapy, secondary)
• Male
• Middle Aged
• Neurotoxicity Syndromes (cerebrospinal fluid, etiology, psychology)